JP2022506368A5 - - Google Patents

Info

Publication number
JP2022506368A5
JP2022506368A5 JP2021523696A JP2021523696A JP2022506368A5 JP 2022506368 A5 JP2022506368 A5 JP 2022506368A5 JP 2021523696 A JP2021523696 A JP 2021523696A JP 2021523696 A JP2021523696 A JP 2021523696A JP 2022506368 A5 JP2022506368 A5 JP 2022506368A5
Authority
JP
Japan
Prior art keywords
item
human patient
approximately
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506368A (ja
JP7459086B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/080362 external-priority patent/WO2020094698A2/en
Publication of JP2022506368A publication Critical patent/JP2022506368A/ja
Publication of JP2022506368A5 publication Critical patent/JP2022506368A5/ja
Application granted granted Critical
Publication of JP7459086B2 publication Critical patent/JP7459086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523696A 2018-11-07 2019-11-06 エストロゲン依存性障害の治療のための組成物及び方法 Active JP7459086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756946P 2018-11-07 2018-11-07
US62/756,946 2018-11-07
PCT/EP2019/080362 WO2020094698A2 (en) 2018-11-07 2019-11-06 Compositions and methods for the treatment of estrogen-dependent disorders

Publications (3)

Publication Number Publication Date
JP2022506368A JP2022506368A (ja) 2022-01-17
JP2022506368A5 true JP2022506368A5 (enExample) 2022-11-15
JP7459086B2 JP7459086B2 (ja) 2024-04-01

Family

ID=68618113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523696A Active JP7459086B2 (ja) 2018-11-07 2019-11-06 エストロゲン依存性障害の治療のための組成物及び方法

Country Status (7)

Country Link
US (1) US20230067378A1 (enExample)
EP (1) EP3876943A2 (enExample)
JP (1) JP7459086B2 (enExample)
KR (1) KR20210100623A (enExample)
MA (1) MA54150A (enExample)
SG (1) SG11202104053TA (enExample)
WO (1) WO2020094698A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
EP4009977A2 (en) * 2019-08-08 2022-06-15 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CA3185151A1 (en) * 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
MA71568A (fr) * 2022-08-16 2025-05-30 Cms Research & Development Pte. Ltd. Forme saline et forme cristalline de dérivé de thiénopyrimidinone
WO2026060502A1 (pt) * 2024-09-23 2026-03-26 Klautau Leite Ana Paula Sistema de diagnóstico por imagem da endometriose profunda e/ou adenomiose e método de análise de exames de imagem

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7102201A (en) 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives
PT1591446E (pt) 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
CA2531508C (en) 2003-07-07 2013-10-08 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
RU2418803C2 (ru) 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
CA2788533C (en) 2010-02-10 2018-03-06 Kissei Pharmaceutical Co., Ltd. Choline salt of fused heterocyclic derivative and pharmaceutical composition containing the same
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
BR112019002513A2 (pt) * 2016-08-08 2019-05-14 Kissei Pharmaceutical Co., Ltd. uso e dosagem de agentes terapêuticos para endometriose
EP4509173A3 (en) * 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
JP2021531236A (ja) * 2018-04-19 2021-11-18 アッヴィ・インコーポレイテッド 重度の月経出血を治療する方法

Similar Documents

Publication Publication Date Title
JP2020522571A5 (enExample)
KR102884301B1 (ko) 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
JPH09508418A (ja) エストロゲン依存症の治療
KR20090094437A (ko) 상승-약량 연장 주기 요법을 이용한 호르몬 치료 방법
JP2020522525A5 (enExample)
JP2021098702A (ja) 選択的プロゲステロン受容体モジュレーター(sprm)レジメン
CN1192145A (zh) 最大限度地减少骨损失的方法
JP6818047B2 (ja) ロガニンまたはその誘導体を有効成分として含有する女性更年期症候群の予防、改善または治療用組成物
JP6691193B2 (ja) プロゲステロン受容体アンタゴニスト剤形
AU2020325655A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR100232833B1 (ko) 수정의 방지 또는 억제방법
JP2006306872A (ja) 選択的エストロゲン受容体修飾因子及びアロマターゼ阻害剤の組み合わせよりなる医薬組成物及び方法
TWI835716B (zh) 治療良性前列腺增殖徵候與症狀之四氫環戊[b]吲哚化合物與磷酸二酯酶抑制劑
WO2006054938A1 (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
JP2004520411A5 (enExample)
HK40057959A (en) Selective progesterone receptor modulator (sprm) regimen
Luu et al. Obese Women Exhibit Reduced Inhibin B and Estradiol SecretionFollowing Pulsatile Intravenous FSH Administration
HK40010025A (en) Progesterone receptor antagonist dosage form
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
JP2020114805A (ja) エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び/又は器質的病変の治療剤